Title |
Emerging treatment options for management of malignant ascites in patients with ovarian cancer
|
---|---|
Published in |
International Journal of Women's Health, August 2012
|
DOI | 10.2147/ijwh.s29467 |
Pubmed ID | |
Authors |
Ramez N Eskander, Krishnansu S Tewari |
Abstract |
Malignant ascites affects approximately 10% of patients with recurrent epithelial ovarian cancer and is associated with troublesome symptoms, including abdominal pressure and distension, dyspnea, bloating, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced ovarian cancer. In this article, we discuss currently existing options for the treatment of ascites associated with ovarian cancer, and review the literature as it pertains to novel, targeted therapies. Specifically, preclinical and clinical trials exploring the use of the antiangiogenic agents, bevacizumab and vascular endothelial growth factor-trap, as well as the nonangiogenic agent, catumaxomab, will be reviewed. Despite current limitations in treatment, knowledge regarding management options in the palliation of ascites is critical to practicing physicians. Ultimately, as with all novel therapies, symptom relief and treatment goals must be weighed against patient discomfort and potentially significant adverse events. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Indonesia | 1 | 3% |
United Kingdom | 1 | 3% |
Denmark | 1 | 3% |
Unknown | 28 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 19% |
Student > Ph. D. Student | 5 | 16% |
Researcher | 4 | 13% |
Student > Bachelor | 3 | 10% |
Student > Postgraduate | 3 | 10% |
Other | 5 | 16% |
Unknown | 5 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 32% |
Biochemistry, Genetics and Molecular Biology | 5 | 16% |
Agricultural and Biological Sciences | 4 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Business, Management and Accounting | 1 | 3% |
Other | 2 | 6% |
Unknown | 7 | 23% |